Acute myeloid leukemia (AML) is an aggressive form of blood cancer. It affects people of all ages but is most common in those over 65. Around 150 people are diagnosed with the disease each year in ...

Acute myeloid leukaemia (AML) is an aggressive form of blood cancer. It affects people of all ages but is most common in ...

An fresh look at trial results that propelled the only FDA approval of a chimeric antigen receptor (CAR) T-cell therapy for mantle cell lymphoma (MCL) shows prior treatment with ibrutinib, a ...

Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals. Under this framework, MRD negativity is ...

A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...

STEMart announces the expansion of its genetic toxicology capabilities with the In Vivo Rat Micronucleus Test services.

The successful clinical validation of AlloHeme represents a key milestone in CareDx's Transplant+ strategy, expanding the Company's precision medicine capabilities into cell therapy, hematology, and ...

A new breakthrough study led by researchers at the University of Minnesota Twin Cities could explain why patients with the ...

A new breakthrough study led by researchers at the University of Minnesota Twin Cities could explain why patients with the same genetic sickle cell mutation experience different levels of pain, organ ...

CareDx (NASDAQ:CDNA) used an investor webcast to outline its “Transplant Plus” expansion into cell therapy and to highlight ...

Blood vessels twist, branch, narrow, and balloon in ways that dramatically affect how blood flows — but most lab models have long treated them like straight pipes. Researchers at Texas A&M have now ...